Rearrangement During Transfection (RET) Fusions and Their Role as Oncogenic Drivers

Web Exclusives - Lung Cancer

The discovery of chromosomal rearrangements resulting in oncogenic fusions has revealed new drug targets and highlighted the importance of molecular biomarker identification for many types of cancer. One example is rearrangement during transfection (RET) fusions, wherein the RET receptor tyrosine kinase fuses with a partner molecule, and this fusion is capable of oncogenic activity.1-4

Typically, RET is present on the surface of tissues in the nervous system, adrenal medulla, and thyroid, among other tissues.1,5 It is important for renal organogenesis and development of the enteric nervous system as well as for neural crest development.2,6 The RET receptor contains 3 domains (ie, extracellular domain, transmembrane domain, and intracellular tyrosine kinase domain), and activation of RET requires indirect ligand binding to form a multimeric protein complex.2,7 These ligands belong to the glial-derived neurotropic factor (GDNF) family and bind to a GDNF family receptor-alpha.8 This complex then mediates RET dimerization and autophosphorylation, which activates RET.7 Once activated, RET engages intracellular signaling pathways, including the mitogen‐activated protein kinase, PI3K/AKT, and Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathways.1,2 Activation of these pathways results in cell proliferation, migration, survival, and differentiation.2,8

Changes in RET can be associated with a gain or a loss of function. Loss-of-function mutations in RET can result in Hirschsprung’s disease or congenital absence of enteric ganglia.1,2 Gain-of-function changes, including mutations and fusions, have been associated with malignancy.1,2 Chromosomal rearrangements involving RET generate fusion transcripts that pair the 3′ end of RET with the 5′ end of another gene.2 These fusions can result in ligand-independent activation of RET, and because in all fusions the tyrosine kinase function of RET is preserved,2 this results in unchecked cellular proliferation.1,3 Several fusion partners have been identified for RET, including CCDC6, NCOA4, PRKAR1A, TRIM24, and KIF5B.1,2 RET mutations or fusions have been identified in papillary thyroid cancer (RET fusions present in 5%-40%), medullary thyroid cancer (gain-of-function point mutations present in up to 50% of patients), and non–small-cell lung cancer (NSCLC; RET rearrangements present in 1%-2%).2 In addition, germline mutations in RET are present in patients with multiple endocrine neoplasia.3

Similar to other oncogenic driver mutations in lung cancer, RET fusions in NSCLC are typically associated with patients who are younger in age (<60 years), female, nonsmokers, and of Asian descent.1,8 RET fusion partners identified in NSCLC include KIF5B, CCDC6, TRIM33, and NCOA4. Whereas CCDC6, TRIM33, and NCOA4 have also been identified as fusion partners in papillary thyroid cancer, KIF5B is the most common fusion partner in NSCLC.2

There is significant evidence that RET fusions may be meaningful drug targets in NSCLC.1,2 In cell-line studies, treatment of cells expressing the KIF5B-RET fusion with multikinase inhibitors with anti-RET activity result in inhibition of growth.2 These agents have modest clinical activity.8 However, selective RET inhibitors have demonstrated significant clinical activity and manageable toxicity.8 As early trials have demonstrated clinically meaningful efficacy, the evidence that RET rearrangements in NSCLC may be treatable with targeted RET inhibitors is encouraging and may predict a paradigm shift in the treatment of patients with RET-positive NSCLC.8


  1. O’Leary C, Xu W, Pavlakis N, et al. Rearranged during transfection fusions in non–small-cell lung cancer. Cancers (Basel). 2019;11:620.
  2. Gainor JF, Shaw AT. Novel targets in non–small-cell lung cancer: ROS1 and RET fusions. Oncologist. 2013;18:865-875.
  3. Kato S, Subbiah V, Marchlik E, et al. RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients. Clin Cancer Res. 2017;23:1988-1997.
  4. Takeuchi K. Discovery stories of RET fusions in lung cancer: mini-review. Front Physiol. 2019;10:216.
  5. Takaya K, Yoshimasa T, Arai H, et al. Expression of the RET proto-oncogene in normal human tissues, pheochromocytomas, and other tumors of neural chest origin. J Mol Med (Berl). 1996;74:617-621.
  6. Ibáñez CF. Structure and physiology of the RET receptor tyrosine kinase. Cold Spring Harb Perspect Biol. 2013;5:a009134.
  7. Drilon A, Hu ZI, Lai GGY, Tan DSW. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol. 2018;15:151-167.
  8. Ackermann CJ, Stock G, Tay R, et al. Targeted therapy for RET-rearranged non–small-cell lung cancer: clinical development and future directions. Onco Targets Ther. 2019;12:7857-7864.
Related Items
Lung Cancer Screening More Cost-Effective When Using Risk Model-Based Strategies
TOP - March 2023 Vol 16, No 2 published on March 6, 2023 in Lung Cancer
Sotorasib Achieves Durable Responses in Patients with Metastatic NSCLC and KRAS Mutation
Patricia Stewart
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in Lung Cancer
Neoadjuvant Nivolumab plus Chemotherapy May Be a New Standard of Care in Resectable NSCLC
Phoebe Starr
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in Lung Cancer
Antibody–Drug Conjugate Shows Promising Activity in Patients with Advanced or Metastatic EGFR Mutation–Positive NSCLC
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Lung Cancer
Amivantamab plus Lazertinib Combo Improves Response in Osimertinib-Resistant EGFR-Positive NSCLC
Patricia Stewart
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Lung Cancer
Sotorasib Shows Encouraging Activity in Patients with NSCLC and KRAS p.G12C Mutation
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Neoadjuvant Nivolumab plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable NSCLC
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Educating NSCLC Patients on Adverse Event Management
Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T), Cathy Simmons, RN, BSN, ONN-CG(T), Lauren Welch, MSN, NP-C, AOCNP
Videos published on July 8, 2021 in Interview with the Innovators, Lung Cancer, Adverse Events
Addressing Lung Cancer Screening Disparities in LGBT Populations
William Ackerman
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Lung Cancer
Analysis Identifies EGFR as Most Common Mutation in Women with Lung Cancer and No Smoking History
William Ackerman
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Lung Cancer
Last modified: July 22, 2021